Re: 'ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the Safety of Targeted and Biological Therapies' by Mikulska Et Al.

Clinical Microbiology and Infection - United Kingdom
doi 10.1016/j.cmi.2018.12.025
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

New Perspectives on Biological HDL-targeted Therapies

Expert Opinion on Biological Therapy
Drug DiscoveryClinical BiochemistryPharmacology
2017English

Prospective Evaluation of the Cardiac Safety of HER2-targeted Therapies in Patients With HER2-positive Breast Cancer and Compromised Heart Function: The SAFE-HEaRt Study

Breast Cancer Research and Treatment
Cancer ResearchOncology
2019English

Review by Hui-Yuen Et Al. Targeted B-Cell Therapies in the Treatment of Adult and Paediatric Systemic Lupus Erythematosus

Lupus
Rheumatology
2016English

Cytomegalovirus in Immune Compromised Hosts.

BMJ
1977English

Emerging Treatment Models in Rheumatology: IgG4-Related Disease: Insights Into Human Immunology and Targeted Therapies. Comments on the Article by Perugino Et Al

Arthritis and Rheumatology
RheumatologyAllergyImmunology
2018English

Tolerability and Safety of Biological Therapies for Psoriasis in Daily Clinical Practice: A Study of 103 Italian Patients

Acta Dermato-Venereologica
DermatologyMedicine
2011English

Systemic Cytotoxic and Biological Therapies of Colorectal Liver Metastases: Expert Consensus Statement

HPB
HepatologyGastroenterology
2013English

Consensus Document on Dog and Cat Allergy

Allergy: European Journal of Allergy and Clinical Immunology
AllergyImmunology
2018English

Comment on Study by Perkins Et Al.

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2002English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy